SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development(1,2). Here we show that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas (SCCs) of the lung and esophagus contains the transcription factor gene SOX2, which is mutated in hereditary human esophageal malformations(3), is necessary for normal esophageal squamous development(4), promotes differentiation and proliferation of basal tracheal cells(5) and cooperates in induction of pluripotent stem cells(6-8). SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 here cooperated with FOXE1 or FGFR2 to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of markers of both squamous differentiation and pluripotency. These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.

Ruth L. Kirschstein NRSA

KWF Kankerbestrijding

US Department of Defense (DoD)

National Cancer Institute (NCI/NIH)[K08CA134931]

National Cancer Institute (NCI/NIH)[P50CA70907]

National Cancer Institute (NCI/NIH)[R33CA128625]

National Cancer Institute (NCI/NIH)[R01CA071606-12]

National Cancer Institute (NCI/NIH)[P01CA098101-05]

National Cancer Institute (NCI/NIH)[R01CA109038]

National Cancer Institute (NCI/NIH)[P50CA90578]

Genentech, Inc.

Sara Thomas Monopoli Lung Cancer Research Fund

Seaman Corporation Fund for Lung Cancer Research